JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Mehmet Ates
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ates, M.
Right arrow Articles by Altundag, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ates, M.
Right arrow Articles by Altundag, K.
Related Collections
Right arrow Lung - cancer
Right arrow Molecular biology
Right arrowRelated Article

J Thorac Cardiovasc Surg 2005;130:1484-1485
© 2005 The American Association for Thoracic Surgery

Letter to the Editor

Association between cyclooxygenase and epidermal growth factor receptor pathways in non–small cell lung cancer

Mehmet Ates, MD a , Ozden Altundag, MD b , Serdal Aktolga, MD c , Kadri Altundag, MD d

a Department of Cardiovascular Surgery, Siyami Ersek Thoracic and Cardiovascular Education and Research Hospital, Istanbul, Turkey
b 8181 Fannin St No. 728, Houston, TX 77054
c Department of Internal Medicine, Marmara University Medical School, Istanbul, Turkey
d Department of Medical Oncology, Hacettepe University Medical School, Ankara, Turkey

The first 20% of the full text of this article appears below.

To the Editor:

We read with great interest the article by Sievers and associates. 1 Go In their orthotopic murine model of lung cancer with adenocarcinoma, they showed inhibition of tumor growth with a low-dose cyclooxygenase-2 (COX-2) inhibitor, celecoxib. In their article, they discussed different mechanisms of association between COX-2 inhibition and attenuation of tumor growth in non–small cell lung cancer (NSCLC), and we want to propose another. COX (or prostaglandin endoperoxide synthase) catalyzes the conversion of arachidonic acid to prostaglandin (PG) H2. This unstable . . . [Full Text of this Article]


Related Article

Reply to the Editor
Eric Sievers and R.M. Bremner
J. Thorac. Cardiovasc. Surg. 2005 130: 1485. [Extract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.